Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Marco Haselager"'
Autor:
Karoline Kielbassa, Marco Haselager, Danique Bax, Bianca van Driel, Mark-David Levin, Sabina Kersting, Rebecka Svanberg, Carsten U. Niemann, Arnon P. Kater, Eric Eldering
Publikováno v:
HemaSphere, Vol 7, p e7227685 (2023)
Externí odkaz:
https://doaj.org/article/63f6b909adb44b399ece053994855bb8
Autor:
Marco Haselager, Rachel Thijssen, Arnon P. Kater, Christopher West, Roel J. W. van Kampen, Elaine Willmore, Simon P. Mackay, Eric Eldering, Louise C. Young
Publikováno v:
Cell Death and Differentiation
Cell death and differentiation, 28(5), 1658-1668. Nature Publishing Group
Cell death and differentiation, 28(5), 1658-1668. Nature Publishing Group
In chronic lymphocytic leukemia (CLL), the lymph node (LN) microenvironment delivers critical survival signals by inducing the expression of anti-apoptotic Bcl-2 members Bcl-XL, Bfl-1, and Mcl-1, resulting in apoptosis blockade. We determined previou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cd804475140f3409a2804c3a88a8de7
http://europepmc.org/articles/PMC8167103
http://europepmc.org/articles/PMC8167103
Autor:
Jannie Borst, Constantine S. Tam, Danique Johanna Cornelia Bax, Stacey M. Fernandes, Julie Dubois, Jennifer R. Brown, Arnon P. Kater, Johanna ter Burg, Francesco Forconi, Eric Eldering, Marco Haselager, Karoline Kielbassa, Giorgia Chiodin
Publikováno v:
Blood, 136(25), 2918-2926. AMER SOC HEMATOLOGY
Blood, 136(25), 2918-2926. American Society of Hematology
Blood, 136(25), 2918-2926. American Society of Hematology
Chronic lymphocytic leukemia (CLL) cells cycle between lymph node (LN) and peripheral blood (PB) and display major shifts in Bcl-2 family members between those compartments. Specifically, Bcl-XL and Mcl-1, which are not targeted by the Bcl-2 inhibito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f522c6973b370e1a109f8f321998c424
https://doi.org/10.1182/blood.2019004326
https://doi.org/10.1182/blood.2019004326
Ibrutinib Treatment in CLL Interrupts CD40 Signaling Capacity and Sensitizes CLL Cells to Venetoclax
Autor:
Rebecka Svanberg, Marco Haselager, Arnon P. Kater, Carsten Utoft Niemann, Mark-David Levin, Peter E. Westerweel, Karoline Kielbassa, Eric Eldering, Danique Johanna Cornelia Bax, Julie Dubois
Publikováno v:
Blood. 138:1545-1545
Background: For proliferation and survival, chronic lymphocytic leukemia (CLL) cells depend on interactions with cells and soluble factors present in the tumor microenvironment (TME). These interactions also increase expression of B-cell leukemia/lym
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1523867a81b9feaedb4f742473212f9d
https://doi.org/10.1182/blood-2021-152222
https://doi.org/10.1182/blood-2021-152222
Publikováno v:
Blood. 136:47-48
INTRODUCTION. Primary chronic lymphocytic leukemia (CLL) cells, despite originating from a proliferative disease, rapidly undergo apoptosis in vitro in absence of microenvironmental survival signals1. Although co-culture with stromal cells or the add
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc2f0b7a2a1898a478f6ef729a392b0e
https://doi.org/10.1182/blood-2020-141962
https://doi.org/10.1182/blood-2020-141962
Publikováno v:
Blood. 134:5449-5449
INTRODUCTION. The Bcl-2 inhibitor Venetoclax provides profound reductions in circulating chronic lymphocytic leukemia (CLL) cells in the majority of patients. However, lymph node (LN) responses are less robust, which may be linked to an acquired resi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::078374eff378c94abb985c4f359bbb0e
https://doi.org/10.1182/blood-2019-126788
https://doi.org/10.1182/blood-2019-126788